The first domestic!Baoshan Enterprise Bluebird Biological New Crown MRNA Chimicular vaccine is approved by clinical clinical

Recently, a new type of coronary virus mutant strain (c code: RQ3013), a new coronary virus mutant strain jointly developed by Baoshan Enterprise Bluebird Biological Joint Fudan University and Watson Biology, officially obtained the approval of clinical trials of the State Drug Administration, will be about The clinical trial was conducted in early September.

RQ3013 is the first MRNA chimeric vaccine in China to enter the clinical vaccine. Coding the new coronary virus S full -length protein and the chimeric part of the key mutation positions. The sequence contains multiple Omeko strains. Pre -clinical studies have shown that the vaccine has good safety and protection effects, and has a certain cross neutralization for the main new coronary virus VOCs including OMICRON strains.

Bluebird creating the "Strategic Cooperation Agreement" with Fudan University and Watson Biology before. It strengthened its respective advantages through industry -university -research, and was committed to creating an innovative and efficient MRNA vaccine technology platform.

The RQ3013 chimeric vaccine is independently developed from key core technologies such as antigen design, MRNA molecular optimization, to production processes, quality standards and other key core technologies.

In the future, the three parties will continue to strengthen cooperation to continue to work hard in clinical trials, key raw auxiliary materials production, domestic MRNA vaccine production, etc., and establish my country's independent and controllable MRNA vaccine research and development and industrialization technology platform. This is of great strategic significance for the response to the new crown pneumonia's epidemic and the new causes of infectious diseases that may occur in the future.

Source: Shanghai Baoshan official WeChat

- END -